|Bid||3.85 x 3000|
|Ask||4.20 x 3000|
|Day's Range||3.83 - 4.15|
|52 Week Range||3.20 - 6.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 22, 2018 - Oct 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.70|
How far off is Accuray Incorporated (NASDAQ:ARAY) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Scientific ...
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Warning! GuruFocus has detected 1 Warning Sign with ARAY. For the last quarter Accuray Inc reported a revenue of $113.8 million, compared with the revenue of $112.1 million during the same period a year ago.
In August, nine analysts are covering Varian Medical Systems (VAR) stock. Three of them have given the stock a “strong buy” rating, three have given it a “hold,” and three have given it a “sell.” The mean rating for VAR stock is 2.67 with a target price of $122. That implies an upside potential of 9.1% over its closing price of $111.83 on August 20.
SUNNYVALE, Calif. (AP) _ Accuray Inc. (ARAY) on Thursday reported a loss of $946,000 in its fiscal fourth quarter. On a per-share basis, the Sunnyvale, California-based company said it had a loss of 1 cent. The radiation oncology company posted revenue of $113.8 million in the period.
SUNNYVALE, Calif. , Aug. 16, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2018 . Q4 Fiscal 2018 and Recent ...
NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Accuray Incorporated (NASDAQ: ARAY ) will be discussing their earnings results in their Q4 Earnings Call to be held on August 16, 2018 at 4:30 PM Eastern Time. ...
SUNNYVALE, Calif., July 25, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Addenbrooke's Hospital clinical team has treated the first cancer patients in the United Kingdom with the innovative Radixact® System. Addenbrooke's Hospital, part of the Cambridge University Hospitals NHS Foundation Trust, purchased one Radixact System through the NHS England radiotherapy equipment upgrade fund, with a second system funded by the Trust.
In addition, he will serve on the Board's Audit Committee. With Mr. Whitters' appointment, the Accuray Board has been expanded to eight members. Mr. Whitters brings significant public company governance experience in the medical technology and medical device industries to Accuray.
SUNNYVALE, Calif. , July 19, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2018 ended June 30, 2018 on Thursday, August 16, 2018 after ...
Stock Research Monitor: WMGI, ZBH, and ARAY LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on VRAY sign up now at www.wallstequities.com/registration . Pre-market today, WallStEquities.com ...
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accuray ...
The Atomic Energy Regulatory Board (AERB) approves Accuray's (ARAY) Radixact X9 in India; exposes the company to AI and Mechatronic trends.
Accuray Incorporated (NASDAQ:ARAY), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS over the last few months, increasingRead More...
SUNNYVALE, Calif., June 21, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Company has received an Atomic Energy Regulatory Board (AERB) Type Approval for its Radixact® X9 System in India. The AERB Type Approval indicates the device conforms to established safety standards and will enable Accuray to sell, and Indian hospitals throughout the country to import, this next-generation TomoTherapy® platform. The Radixact and TomoTherapy Systems are the only radiation therapy devices capable of delivering treatment both from clinician-specified beam angles and by continuous delivery of radiation from 360 degrees around the patient, expanding the type of cancer cases that can be precisely and efficiently treated on a daily basis.
This Monday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), Accuray Inc. (NASDAQ: ARAY), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). All you have to do is sign up today for this free limited time offer by clicking the link below.
Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SUNNYVALE, Calif., May 30, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients being treated for leukemia and multiple myeloma for a bone marrow transplant. TBI involves irradiation of the entire body, elevating the need for precision, accuracy and homogeneity in radiation dose delivery. The TomoTherapy platform's unique architecture enables efficient and extremely effective delivery of radiation over large areas of the patient, making it a valuable part of the bone marrow transplantation conditioning regimen.